• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Pathogen Reduced Platelets are Non-Inferior to Conventional Platelets for Hematology Patients

October 28, 2021

Results for the PIPER Phase 4 study of psoralen-UVA pathogen reduced platelets (PRPC) (Cerus Corporation) following transfusion were recently presented at the 2021 Annual AABB meeting.   In this prospective, open-label, two-arm study at 15 U.S. hospitals, 1068 hematology-oncology platelet-dependent patients (mean age, 57.0 years) received PRPC, and 1223 comparable patients (mean age, 50.6 years) received conventional platelet concentrates (CPC).  Patients who received PRPC were less likely to have severe pulmonary injury; 2.9% of patients who received PRPC required mechanical ventilation compared to 4.6% of patients who received CPC (p=0.039).  Furthermore, other clinically significant adverse events were comparable in both study arms.  RBC utilization was similar, and no differences in safety were observed.  However, data on increases in platelet count increment were not assessed.  Preliminary results from the PIPER study suggest that PRPC are safe for routine clinical use in hematology-oncology patients.

Reference:

Snyder EL, Wheeler A, Refaai MA, Cohn CS, et al.  The PIPER Phase 4 Study:  Pathogen inactivated platelets entering routine practice.  2021 Virtual AABB Annual Meeting, October 17-19, 2021. Transfusion 2021

Filed Under

  • News
  • Platelet Transfusion

Recommended

  • Annual U.K. SHOT Report on Serious Hazards of Transfusions

  • Erythroid Enhancer of BCL11A Gene May Determine Fetal Hemoglobin Levels

  • Donor Age, Sex, and Hemoglobin Levels Associated with RBC Transfusion Effectiveness in Very Low Birth Weight Infants

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Directed Blood Donations Should be Limited

  • Babesia Infection Reduces Red Cell Deformability

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley